


## PD173952

<b>Cat. No.:</b>	HY-122113
<b>CAS No.:</b>	305820-75-1
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>21</sub> Cl <sub>2</sub> N <sub>5</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	482.36
<b>Target:</b>	Src; Bcr-Abl; Apoptosis; Wee1
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK; Apoptosis; Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PD173952 is a tyrosine kinases inhibitor with IC <sub>50</sub> s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a K <sub>i</sub> of 8.1 nM. PD173952 induces apoptosis <sup>[1][2]</sup> .																					
<b>IC<sub>50</sub> &amp; Target</b>	Lyn 0.3 nM (IC <sub>50</sub> )	Abl 1.7 nM (IC <sub>50</sub> )	Csk 6.6 nM (IC <sub>50</sub> )	Myt1 8.1 nM (K <sub>i</sub> )																		
<b>In Vitro</b>	<p>PD173952 (0-1000 nM; 12 h) inhibits tyrosine phosphorylation of p210<sup>Bcr-Abl</sup> and CrkL in K562 cells in a concentration-dependent manner<sup>[1]</sup>.</p> <p>PD173952 (0.5 μM; 1-4 days) inhibits K562 cell viability<sup>[1]</sup>.</p> <p>PD173952 (0.5 μM; 24 and 48 h) induces apoptosis of K562 and MEG-01 cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 25, 50, 100, 200, 500 and 1000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited tyrosine phosphorylation of p210<sup>Bcr-Abl</sup> and CrkL.</td> </tr> </table> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1-4 days</td> </tr> <tr> <td>Result:</td> <td>Caused cell death in a time-dependent manner.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 and MEG-01 cells</td> </tr> </table>				Cell Line:	K562 cells	Concentration:	0, 25, 50, 100, 200, 500 and 1000 nM	Incubation Time:	12 h	Result:	Inhibited tyrosine phosphorylation of p210 <sup>Bcr-Abl</sup> and CrkL.	Cell Line:	K562 cells	Concentration:	0.5 μM	Incubation Time:	1-4 days	Result:	Caused cell death in a time-dependent manner.	Cell Line:	K562 and MEG-01 cells
Cell Line:	K562 cells																					
Concentration:	0, 25, 50, 100, 200, 500 and 1000 nM																					
Incubation Time:	12 h																					
Result:	Inhibited tyrosine phosphorylation of p210 <sup>Bcr-Abl</sup> and CrkL.																					
Cell Line:	K562 cells																					
Concentration:	0.5 μM																					
Incubation Time:	1-4 days																					
Result:	Caused cell death in a time-dependent manner.																					
Cell Line:	K562 and MEG-01 cells																					

---

Concentration:	0.5 $\mu$ M
Incubation Time:	24 and 48 h
Result:	85-kDa PARP fragment was detected.

---

## REFERENCES

---

[1]. Dorsey JF, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. *Leukemia*. 2002 Sep;16(9):1589-95.

[2]. Wichapong K, et al. Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. *J Chem Inf Model*. 2014 Mar 24;54(3):881-93.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA